Jami Way's doctors say she is a shining example of the improved outcomes possible with new treatment options for early-stage lung cancer. (Photo by Joshua Sudock/UCLA Health)
Jami Way recites a mantra out loud before swallowing a pill each morning intended to prevent a return of lung cancer. Way takes Tagrisso, a targeted therapy for non-small cell, early-stage epidermal growth factor receptor (EGFR)-positive lung cancer, where a mutation in the tumor causes cancer to spread quickly.
UCLA Health participated in a global clinical trial that led to expanded use of the drug in 2020, the year Way was diagnosed. Early data showing a big reduction in the risk of recurrence or death among people who underwent surgical removal of their tumors led to expedited approval from the U.S. Food and Drug Administration.
Click here to read the UCLA Healtn Connect blog.